{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:08:41Z","timestamp":1778940521622,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Colorectal cancer(CRC) is the third most commonly diagnosed malignancy with a rising global incidence. CRC shares many risk factors with other malignancies and may occur as a part of hereditary cancer syndromes. This retrospective cohort study aims to evaluate outcomes in patients with CRC and a history of prior malignancy to identify potential implications for personalized management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The National Cancer Database was queried from 2004 to 2022 for patients diagnosed with CRC, who were stratified into two cohorts: those with and without malignancies prior to CRC diagnosis. Propensity score matching was performed to balance sociodemographic characteristics, and logistic regression was used to estimate odds ratios(ORs) for tumor and treatment characteristics. Subsequently, a Cox proportional hazards model was fit to assess the association of having prior malignancies and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 576,076 patients were included, with 288,038 in each cohort. Patients with prior malignancies had significantly lower odds of KRAS mutation(OR\u2009=\u20090.86, 95% CI:0.83\u20130.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), abnormal CEA levels(OR\u2009=\u20090.95, 95% CI:0.94\u20130.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), perineural invasion(OR\u2009=\u20090.86, 95% CI:0.84\u20130.88,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), early-onset CRC(OR\u2009=\u20090.73, 95% CI:0.71\u20130.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), advanced-stage CRC(OR\u2009=\u20090.77, 95% CI:0.76\u20130.77,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and tumor deposits(OR\u2009=\u20090.82, 95% CI:0.80\u20130.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). These patients also had higher odds of receiving treatment(OR\u2009=\u20091.05, 95% CI:1.02\u20131.08,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). However, they had higher odds of microsatellite instability(OR\u2009=\u20091.20, 95% CI:1.17\u20131.23,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), treatment delays(OR\u2009=\u20091.42, 95% CI:1.40\u20131.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and postoperative readmissions(OR\u2009=\u20091.14, 95% CI:1.11\u20131.17,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients with a history of prior malignancies were associated with higher overall mortality(aHR\u2009=\u20091.19, 95% CI:1.10\u20131.27,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) as well as stage-specific mortality, except for stage 1 CRC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that patients with prior malignancies may require greater preoperative optimization, closer post-discharge monitoring, and proactive efforts to avoid treatment delays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01482-2","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:28:36Z","timestamp":1778938116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and Outcomes of Patients With Malignancies Prior to Colorectal Cancer: A Propensity Score Matched Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Imran","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vraj P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Botterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safia","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasma","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"1482_CR1","unstructured":"Cancer Stat Facts: Colorectal Cancer. 2025 [cited 2025 8\/5\/25]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"key":"1482_CR2","unstructured":"Key Statistics for Colorectal Cancer. 2025 [cited 2025 8\/5\/25]; Available from: https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/about\/key-statistics.html"},{"issue":"2","key":"1482_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1056\/NEJM200007133430201","volume":"343","author":"P Lichtenstein","year":"2000","unstructured":"Lichtenstein P, et al. Environmental and Heritable Factors in the Causation of Cancer \u2014 Analyses of Cohorts of Twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"1482_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ajpath.2017.07.023","volume":"188","author":"GJ Augustus","year":"2018","unstructured":"Augustus GJ, Ellis NA. Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. Am J Pathol. 2018;188(2):291\u2013303.","journal-title":"Am J Pathol"},{"key":"1482_CR5","doi-asserted-by":"crossref","unstructured":"Yu H et al. Familial associations of colorectal cancer with other cancers. Sci Rep 2017; 7(1).","DOI":"10.1038\/s41598-017-05732-z"},{"issue":"2","key":"1482_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/sj.bjc.6601509","volume":"90","author":"CJ Stein","year":"2004","unstructured":"Stein CJ, Colditz GA. Modifiable risk factors for cancer. Br J Cancer. 2004;90(2):299\u2013303.","journal-title":"Br J Cancer"},{"issue":"4","key":"1482_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00423-009-0553-1","volume":"395","author":"W-S Lee","year":"2010","unstructured":"Lee W-S, et al. Multiple primary malignancies involving colorectal cancer\u2014clinical characteristics and prognosis with reference to surveillance. Langenbeck\u2019s Archives Surg. 2010;395(4):359\u201364.","journal-title":"Langenbeck\u2019s Archives Surg"},{"issue":"6","key":"1482_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jamaoncol.2017.3605","volume":"4","author":"CC Murphy","year":"2018","unstructured":"Murphy CC, Gerber DE, Pruitt SL. Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program. JAMA Oncol. 2018;4(6):832\u20136.","journal-title":"JAMA Oncol"},{"key":"1482_CR9","doi-asserted-by":"crossref","unstructured":"Qiu Y et al. Survival and risk factors for metastatic colorectal cancer patients with a history of prior malignancy. Sci Rep 2025;15(1).","DOI":"10.1038\/s41598-025-88555-7"},{"issue":"6","key":"1482_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1159\/000517271","volume":"102","author":"K Ochiai","year":"2021","unstructured":"Ochiai K, et al. Prognostic Impact and Clinicopathological Features of Multiple Colorectal Cancers and Extracolorectal Malignancies: A Nationwide Retrospective Study. Digestion. 2021;102(6):911\u201320.","journal-title":"Digestion"},{"issue":"2","key":"1482_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.soc.2021.11.002","volume":"31","author":"RH Hollis","year":"2022","unstructured":"Hollis RH, Chu DI. Healthcare Disparities and Colorectal Cancer. Surg Oncol Clin N Am. 2022;31(2):157\u201369.","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"1482_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1186\/s12885-019-6074-6","volume":"19","author":"MJ Al-Husseini","year":"2019","unstructured":"Al-Husseini MJ, et al. Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria. BMC Cancer. 2019;19(1):863.","journal-title":"BMC Cancer"},{"issue":"1","key":"1482_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12885-021-08238-0","volume":"21","author":"D Cavers","year":"2021","unstructured":"Cavers D, et al. Patient and GP experiences of pathways to diagnosis of a second primary cancer: a qualitative study. BMC Cancer. 2021;21(1):496.","journal-title":"BMC Cancer"},{"key":"1482_CR14","doi-asserted-by":"crossref","unstructured":"Massa I et al. Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients. BMC Palliat Care 2018;17(1).","DOI":"10.1186\/s12904-018-0339-8"},{"issue":"6","key":"1482_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","volume":"26","author":"K Mallin","year":"2019","unstructured":"Mallin K, et al. Incident Cases Captured in the National Cancer Database Compared with Those in U.S. Population Based Central Cancer Registries in 2012\u20132014. Ann Surg Oncol. 2019;26(6):1604\u201312.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1482_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1482_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13058-024-01949-9","volume":"26","author":"M Leslie Salewon","year":"2024","unstructured":"Leslie Salewon M, et al. Surgical delay-associated mortality risk varies by subtype in loco-regional breast cancer patients in SEER-Medicare. Breast Cancer Res. 2024;26(1):191.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"1482_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamasurg.2013.1680","volume":"148","author":"EC Smith","year":"2013","unstructured":"Smith EC, Ziogas A, Anton-Culver H. Delay in Surgical Treatment and Survival After Breast Cancer Diagnosis in Young Women by Race\/Ethnicity. JAMA Surg. 2013;148(6):516\u201323.","journal-title":"JAMA Surg"},{"key":"1482_CR19","doi-asserted-by":"crossref","unstructured":"Yang Y et al. KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration. J Clin Med 2023;12(2):709.","DOI":"10.3390\/jcm12020709"},{"issue":"1","key":"1482_CR20","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41598-021-82248-7","volume":"11","author":"J Halamkova","year":"2021","unstructured":"Halamkova J, et al. Second primary malignancies in colorectal cancer patients. Sci Rep. 2021;11(1):2759.","journal-title":"Sci Rep"},{"issue":"1","key":"1482_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/humu.21377","volume":"32","author":"L Gremer","year":"2011","unstructured":"Gremer L, et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat. 2011;32(1):33\u201343.","journal-title":"Hum Mutat"},{"key":"1482_CR22","doi-asserted-by":"crossref","unstructured":"Yildirim HC et al. A narrative review of RAS mutations in early-stage colorectal cancer: mechanisms and clinical implications. Med (Kaunas). 2025;61(3):408.","DOI":"10.3390\/medicina61030408"},{"key":"1482_CR23","doi-asserted-by":"crossref","unstructured":"Melku M et al. Risk Factors of multiple primary cancers among colorectal cancer survivors. Cancers (Basel). 2025;17(13):2145.","DOI":"10.3390\/cancers17132145"},{"key":"1482_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","volume":"189","author":"M Baretti","year":"2018","unstructured":"Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45\u201362.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1482_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/ijpm.ijpm_651_23","volume":"68","author":"XY Chen","year":"2025","unstructured":"Chen XY, et al. Microsatellite instability in colorectal cancer. Indian J Pathol Microbiol. 2025;68(2):255\u201360.","journal-title":"Indian J Pathol Microbiol"},{"issue":"3","key":"1482_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","volume":"7","author":"E Vilar","year":"2010","unstructured":"Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"1482_CR27","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"key":"1482_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.01.112","volume":"94","author":"O Margalit","year":"2018","unstructured":"Margalit O, et al. Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. Eur J Cancer. 2018;94:1\u20135.","journal-title":"Eur J Cancer"},{"key":"1482_CR29","doi-asserted-by":"crossref","unstructured":"Hao C, Zhang G, Zhang L. Serum CEA levels in 49 different types of cancer and noncancer diseases. In: Zhang L, editor. Progress in Molecular Biology and Translational Science. Vol. 162. Academic Press; 2019. p. 213\u2013227.","DOI":"10.1016\/bs.pmbts.2018.12.011"},{"issue":"6","key":"1482_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3393\/ac.2019.11.13","volume":"35","author":"C Hall","year":"2019","unstructured":"Hall C, et al. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann Coloproctol. 2019;35(6):294\u2013305.","journal-title":"Ann Coloproctol"},{"issue":"8","key":"1482_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter NN, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022;40(8):892\u2013910.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1482_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00268-018-4774-8","volume":"43","author":"CH Kim","year":"2019","unstructured":"Kim CH, et al. Prognostic Impact of Perineural Invasion in Rectal Cancer After Neoadjuvant Chemoradiotherapy. World J Surg. 2019;43(1):260\u201372.","journal-title":"World J Surg"},{"key":"1482_CR33","doi-asserted-by":"crossref","unstructured":"Berben L et al. Cancer and aging: two tightly interconnected biological processes. Cancers (Basel), 2021;13(6):1400.","DOI":"10.3390\/cancers13061400"},{"issue":"2","key":"1482_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.seminoncol.2003.12.035","volume":"31","author":"A Luciani","year":"2004","unstructured":"Luciani A, Balducci L. Multiple primary malignancies. Semin Oncol. 2004;31(2):264\u201373.","journal-title":"Semin Oncol"},{"issue":"2","key":"1482_CR35","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4240\/wjgs.v13.i2.164","volume":"13","author":"M Mueller","year":"2021","unstructured":"Mueller M, et al. Colorectal cancer of the young displays distinct features of aggressive tumor biology: A single-center cohort study. World J Gastrointest Surg. 2021;13(2):164\u201375.","journal-title":"World J Gastrointest Surg"},{"issue":"5","key":"1482_CR36","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s11764-021-01095-7","volume":"16","author":"BE Blackburn","year":"2022","unstructured":"Blackburn BE, et al. Preventive service utilization among low-income cancer survivors. J Cancer Surviv. 2022;16(5):1047\u201354.","journal-title":"J Cancer Surviv"},{"issue":"3","key":"1482_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s11764-022-01309-6","volume":"18","author":"MH Tsai","year":"2024","unstructured":"Tsai MH, et al. Receipt of follow-up care plans on colorectal cancer screening among breast, prostate, and lung cancer survivors. J Cancer Surviv. 2024;18(3):781\u201390.","journal-title":"J Cancer Surviv"},{"issue":"4","key":"1482_CR38","doi-asserted-by":"publisher","first-page":"e644","DOI":"10.1634\/theoncologist.2019-0266","volume":"25","author":"H Jia","year":"2020","unstructured":"Jia H, et al. Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis. Oncologist. 2020;25(4):e644\u201350.","journal-title":"Oncologist"},{"issue":"3","key":"1482_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.14740\/wjon2584","volume":"16","author":"SP Ang","year":"2025","unstructured":"Ang SP, et al. Time-to-Treatment Initiation and Its Effect on All-Cause Mortality: Insights From the Surveillance, Epidemiology, and End Results Database. World J Oncol. 2025;16(3):286\u201394.","journal-title":"World J Oncol"},{"issue":"3","key":"1482_CR40","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1007\/s11357-025-01648-z","volume":"47","author":"Z Ungvari","year":"2025","unstructured":"Ungvari Z, et al. Treatment delay significantly increases mortality in colorectal cancer: a meta-analysis. Geroscience. 2025;47(3):5337\u201353.","journal-title":"Geroscience"},{"issue":"10","key":"1482_CR41","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1200\/JOP.18.00175","volume":"14","author":"ML Wong","year":"2018","unstructured":"Wong ML, et al. Comorbidity Assessment in the National Cancer Database for Patients With Surgically Resected Breast, Colorectal, or Lung Cancer (AFT-01, -02, -03). J Oncol Pract. 2018;14(10):e631\u201343.","journal-title":"J Oncol Pract"},{"key":"1482_CR42","doi-asserted-by":"publisher","first-page":"112503","DOI":"10.1016\/j.biopha.2021.112503","volume":"146","author":"J Zeien","year":"2022","unstructured":"Zeien J, et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother. 2022;146:112503.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1482_CR43","doi-asserted-by":"publisher","first-page":"e0134058","DOI":"10.1371\/journal.pone.0134058","volume":"10","author":"IY Kim","year":"2015","unstructured":"Kim IY, Kim BR, Kim YW. Impact of Prior Abdominal Surgery on Rates of Conversion to Open Surgery and Short-Term Outcomes after Laparoscopic Surgery for Colorectal Cancer. PLoS ONE. 2015;10(7):e0134058.","journal-title":"PLoS ONE"},{"issue":"3","key":"1482_CR44","doi-asserted-by":"publisher","first-page":"e0213209","DOI":"10.1371\/journal.pone.0213209","volume":"14","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, et al. Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS ONE. 2019;14(3):e0213209.","journal-title":"PLoS ONE"},{"issue":"14","key":"1482_CR45","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1002\/cam4.4036","volume":"10","author":"SL Pruitt","year":"2021","unstructured":"Pruitt SL, et al. Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. Cancer Med. 2021;10(14):4752\u201367.","journal-title":"Cancer Med"},{"key":"1482_CR46","doi-asserted-by":"publisher","first-page":"175628482091752","DOI":"10.1177\/1756284820917527","volume":"13","author":"G Golshani","year":"2020","unstructured":"Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Th Adv Gastroenterol. 2020;13:1756284820917527.","journal-title":"Th Adv Gastroenterol"},{"issue":"12","key":"1482_CR47","doi-asserted-by":"publisher","first-page":"e2350237","DOI":"10.1001\/jamanetworkopen.2023.50237","volume":"6","author":"Y Satpathy","year":"2023","unstructured":"Satpathy Y, et al. Comparison of Capture Rates of the National Cancer Database Across Race and Ethnicity. JAMA Netw Open. 2023;6(12):e2350237\u20132350237.","journal-title":"JAMA Netw Open"},{"issue":"21","key":"1482_CR48","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1002\/cncr.32325","volume":"125","author":"A Teng","year":"2019","unstructured":"Teng A, et al. Colon cancer as a subsequent malignant neoplasm in young adults. Cancer. 2019;125(21):3749\u201354.","journal-title":"Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01482-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01482-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01482-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:28:44Z","timestamp":1778938124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01482-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01482-2","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}